Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study

Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study

10.1186/s40545-015-0046-2

Saved in:

Bibliographic Details
Main Authors:	Vitry, A, Nguyen, T, Entwistle, V, Roughead, E
Other Authors:	DEAN'S OFFICE (MEDICINE)
Format:	Article
Published:	2020
Subjects:	anthracycline bevacizumab capecitabine docetaxel gemcitabine monoclonal antibody paclitaxel taxane derivative vasculotropin advanced cancer arterial thromboembolism Article bleeding breast cancer cancer survivor controlled study cost effectiveness analysis digestive system perforation drug approval drug efficacy drug marketing drug safety drug withdrawal febrile neutropenia fistula funding glioblastoma health care policy health practitioner human hypertension kidney carcinoma left ventricular systolic dysfunction medical literature metastatic colorectal cancer non small cell lung cancer overall survival posterior reversible encephalopathy syndrome progression free survival proteinuria public health risk management sensory neuropathy venous thromboembolism wound dehiscence
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/180354
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Description
Summary:	10.1186/s40545-015-0046-2